Has Khaled Tolba received payments from drug or device companies?

Yes. Drug and device makers reported $49,962 in general payments to Khaled Tolba across 56 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Khaled Tolba did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Khaled Tolba come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Khaled Tolba

Hematology & Oncology · Seattle, WANPI 1093828311

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,794 of the $49,962 with a category attached, or 65.6%. 6 manufacturers reported payments, led by Merck at 40.4% of the total. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,962in general payments, 2019–2025

Across 56 payments — averaging $892.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$20K
E.r. Squibb & Sons, L.L.C.$12K
AstraZeneca$6K
Foundation Medicine, Inc.$5K
Boehringer Ingelheim International GmbH$4K
Boehringer Ingelheim Pharma GmbH & Co.kg$2K

$255,557in research payments, 2019–2025

Across 35 payments — averaging $7301.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$97K
E.r. Squibb & Sons, L.L.C.$57K
Genentech, Inc.$41K
Merck$34K
Novartis$18K
Astrazeneca UK Limited$5K
plus $3K from 1 others

What the payments were for

Consulting fees$10,20720%
Speaking & faculty fees$32,79466%
Travel & lodging$6,30513%
Food & beverage$6561%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	19	$20,187
E.r. Squibb & Sons, L.L.C.	9	$12,375
AstraZeneca	10	$6,469
Foundation Medicine, Inc.	6	$5,277
Boehringer Ingelheim International GmbH	11	$4,000
Boehringer Ingelheim Pharma GmbH & Co.kg	1	$1,654

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,962 in reported general payments places this provider in the 90th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington →

Other hematology & oncology in Seattle

John PesandoSeattle$15.7M
Jill JohnsenSeattle$991K
Fengting YanSeattle$841K
John PagelSeattle$725K
Lawrence FongSeattle$546K
Langdon MillerSeattle$457K
Mazyar ShadmanSeattle$226K
Catherine LeeSeattle$199K
Celestia HiganoSeattle$164K
Ryan CassadaySeattle$151K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →